ILMN Stock Recent News
ILMN LATEST HEADLINES
The NovaSeq X launch strengthens Illumina's (ILMN) competitive position in high-throughput sequencing.
Illumina, Inc. (NASDAQ:ILMN ) Piper Sandler 35th Annual Healthcare Conference November 29, 2023 11:30 AM ET Company Participants Jacob Thaysen - Chief Executive Officer Conference Call Participants David Westenberg - Piper Sandler David Westenberg All right. We're going to get started.
Illumina, Inc. (NASDAQ:ILMN ) Evercore ISI 6th Annual HealthCONx Conference November 28, 2023 10:50 AM ET Company Participants Joydeep Goswami - Chief Financial Officer Salli Schwartz - Vice President, Investor Relations Conference Call Participants Vijay Kumar - Evercore ISI Vijay Kumar [Starts Abruptly] Everyone for joining us this morning. Pleasure to have with us Illumina.
Illumina (ILMN) introduces a new initiative to drive more equitable access to genomics globally.
As shares of Illumina Inc. ILMN, +5.46% trade near 10-year lows, analysts are reining in expectations for the DNA-sequencing company.
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Ligand Pharmaceuticals (LGND) or Illumina (ILMN). But which of these two stocks offers value investors a better bang for their buck right now?
Illumina (ILMN) shares fell to their lowest level in a decade after the genetic research equipment manufacturer missed revenue estimates and slashed its guidance as customers pulled back on spending.
Illumina Inc.'s stock ILMN, -13.91% fell 14% Friday to put it on track for its lowest close in 10 years, after the company after the maker of DNA-sequencing technology cut its full-year sales and profit guidance after missing revenue estimates for the third quarter. The stock was last quoted at $91.16.
Illumina Inc (NASDAQ:ILMN) shares sank 11% in pre-market trading on Friday after the gene-testing company reduced its annual profit forecast for the second straight quarter, citing weakness in demand for its sequencing instruments, consumables and services. Illumina said it sees its full year 2023 earnings per share (EPS) of between $0.60 to $0.70, falling short of the $0.80 analyst consensus forecast.
Illumina (ILMN) reports solid earnings in the third quarter of 2023 amid a challenging macro environment.